title: Regulatory reforms and GCP clinical trials with new drugs in India.
abstract: Current Indian drug regulations do not allow for toxicology testing and clinical trials in India with compounds or molecules discovered abroad, except for treatments of tropical, cancer and cardiovascular diseases as part of global studies. The number of GCP Phase II/III trials by foreign sponsors has increased dramatically since 1995, attesting to the potential of India for lower cost trials and reduction in drug development costs and time, due to rapid patient recruitment. However, there have been problems with regard to intellectual property protection and adherence to informed consent guidelines. Starting in 2005, a series of regulatory reforms and patent protection will be instituted that are designed to address many of these concerns; the nature of these reforms are presented and discussed. However, sponsors need to pay close attention to informed consent and other ethical issues in Indian trials, which enroll mainly poor and uneducated patients.
authors.affiliation: Pharma Biotech, Geneva, Switzerland. maggonk@lycos.com
authors.forename: Krishan
authors.initials: K
authors.lastname: Maggon
mesh_terms: D017322:Clinical Trials, Phase II as Topic / Q000331:legislation & jurisprudence* / Q000592:standards; D017326:Clinical Trials, Phase III as Topic / Q000331:legislation & jurisprudence* / Q000592:standards; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D015195:Drug Design; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D015507:Drugs, Investigational; D033161:Government Regulation; D006801:Humans; D007194:India; D007258:Informed Consent / Q000941:ethics / Q000331:legislation & jurisprudence; D018973:Intellectual Property; D012107:Research Design
chemical_list: D015507:Drugs, Investigational